

In Silico Docking Analysis Revealed the Potential of Phytochemicals Present in Phyllanthus Amarus and Andrographis Paniculata, Used in Ayurveda Medicine in Inhibiting SARS-CoV-2

Shridhar Hiremath, Vinay Kumar H D, Nandan M, Mantesh M, Shankarappa K S, Venkataravanappa V, Jahir Basha C R, C N Lakshminarayana Reddy

Submitted date: 02/08/2020 • Posted date: 05/08/2020

Licence: CC BY-NC-ND 4.0

Citation information: Hiremath, Shridhar; H D, Vinay Kumar; M, Nandan; M, Mantesh; S, Shankarappa K; V, Venkataravanappa; et al. (2020): In Silico Docking Analysis Revealed the Potential of Phytochemicals Present in Phyllanthus Amarus and Andrographis Paniculata, Used in Ayurveda Medicine in Inhibiting SARS-CoV-2. ChemRxiv. Preprint. <https://doi.org/10.26434/chemrxiv.12751361.v1>

No therapeutics and vaccines are available against SARS-CoV-2 at present. In the current study we have made an attempt to provide preliminary evidences for interaction of 35 phytochemicals from two plants (Phyllanthus amarus and Andrographis paniculata used in Ayurveda) with SARS-CoV-2 proteins (S protein, 3CLpro, PLpro and RdRp) through in silico docking analysis. The docking was performed with the aid of AutoDock Vina and ADME and other pharmacokinetic properties were predicted using SWISSADME and admetSAR




File list (2)


Supplementary figure.pdf (738.72 KiB)

[view on ChemRxiv](#) • [download file](#)

Covid manuscript1.pdf (1.29 MiB)

[view on ChemRxiv](#) • [download file](#)





Supplementary figure 1: A, 2D visualization of interaction between SARS-CoV-2 proteins with phytochemicals from *P. amarus* and *A. paniculata* showing more dock score than remdesivir

A; S protein (6VSB) with a) astragalín, b) kaempferol c) quercetin d) quercetin-3-O-glucoside e) quercitrin f) hinokinin g) corilagin h) furosin i) geraniin j) isoandrographolide k) 19-O-acetyl-14-deoxy-11,12-didehydroandrographolide l) neoandrographolide m) 5-hydroxy-7,8,2',5'-tetramethoxy flavone

B; 3CLpro (6LU7) with a) astragalín, b) quercetin-3-O-glucoside c) quercitrin, d) corilagin e) furosin f) geraniin

C; PLpro(4OVZ) with a) astragalín, b) kaempferol c) quercetin-3-O-glucoside d) hinokinin

D; RdRp (6NUS) with a) quercetin b) quercetin-3-O-glucoside c) quercitrin d) hinokinin e) corilagin f) furosin g) geraniin, h) isoandrographolide i) 14-deoxy-14,15-didehydroandrographolide j) 14-Deoxyandrographolide k) neoandrographolide l) 5-hydroxy-7,8,2',5'-tetramethoxy flavone

Supplementary figure.pdf (738.72 KiB)

[view on ChemRxiv](#) • [download file](#)

***In silico* docking analysis revealed the potential of phytochemicals present in *Phyllanthus amarus* and *Andrographis paniculata*, used in Ayurveda medicine in inhibiting SARS-CoV-2**

Shridhar Hiremath¹, H D Vinay Kumar¹, M Nandan¹, M Mantesh¹, K S Shankarappa², V Venkataravanappa³, C R Jahir Basha⁴, C N Lakshminarayana Reddy^{1*}

¹Department of Plant Pathology, College of Agriculture, University of Agricultural Sciences, GKVK, Bangalore-560065, Karnataka, India

²Department of Plant Pathology, College of Horticulture, Bengaluru-560 065, University of Horticultural Sciences, Bagalkot, Karnataka, India

³CHES, ICAR-Indian Institute of Horticultural Research, Chettalli, Madikeri District-571 248, Karnataka. India

⁴Department of Plant Pathology, ARS, University of Agricultural Sciences (B), Rajavanthi, Pavagada, Tumakur (Dist.), Karnataka, India

* Corresponding author:

Dr. Lakshminarayana Reddy, C N
Department of Plant Pathology
College of Agriculture,
University of Agricultural Sciences,
GKVK, Bangalore-560065, Karnataka, India
E- mail: cnlreddy@gmail.com

Abstract

The *Severe acute respiratory syndrome coronavirus-2* (SARS-CoV-2) has resulted in outbreak of global pandemic, fatal pneumonia in human referred as Coronavirus Disease-2019 (Covid-19). No therapeutics and vaccines are available against SARS-CoV-2 at present, which made it difficult to contain this disease worldwide. Drug discovery and vaccine development against this pandemic virus was put in fast pace across the world. Ayurveda, the age old practice of treating human ailments in India can also be considered in this endeavour, if supported by scientific evidences required for regulatory authorities to use against SARS-CoV-2. With this backdrop, attempt was made to provide preliminary evidences for interaction of 35 phytochemicals from two plants (*Phyllanthus amarus* and *Andrographis paniculata* used in Ayurveda) with SARS-CoV-2 proteins (S protein, 3CLpro, PLpro and RdRp) through *in silico* docking analysis. The nucleotide analogue remdesivir, being used in treatment of SARS-CoV-2 was used as a positive control. The results revealed that, 18 phytochemicals from *P. amarus* and 14 phytochemicals from *A. paniculata* shown binding energy affinity/dock score (< -6.0 kcal/mol). Fourteen phytochemicals from *A. paniculata* also shown binding affinity (up to -9.10 kcal/mol). Further, flavonoids (astragalin,

kaempferol, quercetin, quercetin-3-O-glucoside, quercetin) and tannins (corilagin, furosin, geraniin) present in *P. amarus* have more binding affinity (up to -10.60 kcal/mol) than remdesivir (up to -9.50 kcal/mol). The pharmacokinetic predictions suggest that compounds from the two plants species studied in the current study are found to be non-carcinogenic, water soluble and biologically safe. The phytochemicals present in the extracts of *P. amarus* and *A. paniculata* might may have synergistic effect with action on multiple target sites of SARS-CoV-2. The information generated here might serve as preliminary evidence for anti SARS-CoV-2 activity of phytochemicals present from *P. amarus* and *A. paniculata* and the potential of Ayurveda medicine in combating the virus.

Keywords: Coronavirus, COVID-19, Molecular docking, Natural Ligands, *Andrographis paniculata* and *Phyllanthus amarus*

Introduction

The outbreak of highly transmissible fatal pneumonia in human referred as Coronavirus Disease-2019 (Covid-19) has spread globally (215 countries and territories) with over 16.81 M confirmed cases and over 6,62,095 deaths worldwide as on 31st July 2020 (<https://www.worldometers.info/coronavirus>). Whereas, in India, 15,83,792 people with 34,968 deaths (<https://www.worldometers.info/coronavirus>). According to the International Committee on Taxonomy of Viruses (ICTV), the novel zoonotic pathogenic virus associated with COVID-19 is *Severe acute respiratory syndrome coronavirus 2* (SARS-CoV-2) and the virus species is Severe acute respiratory syndrome-related coronavirus (Gorbalenya *et al.*, 2019). The break out of SARS-CoV-2 has been first reported during December 2019 in Wuhan, Hubei Province, China with a fatality rate of 4 percent (Liu, *et al.*, 2020; Wu *et al.*, 2020; Zhu *et al.*, 2020). Sore throat, dry cough, fever, chills, repeated shaking with chills, muscle pain, headache, loss of taste or smell and respiratory distress are major symptoms induced by SARS-CoV-2 (Cheng *et al.*, 2007). In most severe cases, the clinical presentation of SARS-CoV-2 infection includes pneumonia that progresses to multi-organ failure and even death (Zaki *et al.*, 2012; Machhi *et al.*, 2020). Covid-19 has become global pandemic and created the wide spread fear of death everywhere in the world resulting lockdown in human society (Mandal, 2020). The increasing pandemic potential of SARS-CoV-2 is due to its high human to human transmissible efficiency which makes it difficult to contain (Wu *et al.*, 2020; Zhao, *et al.*, 2020).

The SARS-CoV-2 is a β -coronavirus, belongs to family *Coronaviridae* of order *Nidovirales* (Zhu *et al.*, 2019). It has enveloped positive sense single stranded RNA genome with 33 kilo base (Kb) encoding for 14 open reading frames (ORFs) (Fehr and Perlman, 2015; Guo *et al.* 2020). The genome of SARS-CoV-2 lacks the hemagglutinin-esterase gene. However, it comprises two flanking untranslated regions (UTRs) at 5' end and 3' with 265 and 358 nucleotides, respectively. The first ORF comprises approximately 67 percent of the genome and encodes 16 non-structural proteins (nsps), which were processed by proteolytic cleavage, whereas the remaining 13 ORFs encode for structural proteins and protein accessory (Boopathi *et al.*, 2020; Chan *et al.*, 2020). The nsps mainly include helicase, RNA dependent RNA polymerase (RdRp), 3-Chymotrypsin-like protease (3CLpro), Papain-like protease (PLpro) and others likely to be involved in the transcription and replication of SARS-CoV-2 (Simmons *et al.*, 2005; Boopathi *et al.*, 2020). Four major structural proteins are spike surface glycoprotein (S protein), membrane protein (M), nucleocapsid protein (N), envelope (E). M protein possess N-terminal glycosylated ectodomain at the N-terminal end that consists of three transmembrane domains (TM) and a long C-terminal CT domain (Boopathi *et al.*, 2020; Chan *et al.*, 2020). The M and E proteins are required for virus morphogenesis, assembly, and budding, whereas, S protein is a fusion viral protein comprising two subunits S1 and S2. The S1 subunit consists of receptor-binding domain (RBD), N-terminal domain (NTD) and signal peptide. The S2 subunit comprises two heptad repeat regions known as HR-N and HR-C, which form the coiled-coil structures surrounded by the protein ectodomain (Walls *et al.*, 2020). A furin cleavage site (PRRARS'V) is present in S protein at the interface between S1 and S2 subunits that will be processed during the biogenesis (Coutard *et al.*, 2020). SARS-CoV-2 S protein facilitate the entry of viral particles into the host cell after binding with the host Angiotensin-converting enzyme 2 (ACE-2) (Tortorici and Veasler, 2019) and also determines the host range and cellular tropism (Simmons *et al.*, 2005). Entry of SARS-CoV-2 into host cells is mediated by the cleavage of viral spike protein by host proteases *viz.*, Serine proteases (TMPRSS2) or Cysteine proteases (Cathepsin B/L) (Boopathi *et al.*, 2020; Yan *et al.*, 2020). The ACE2 and TMPRSS2 proteins are prime targets of the coronavirus (Matsuyama *et al.*, 2010; Glowacka *et al.*, 2011; Zhao *et al.*, 2020).

The most direct and simplest strategy to combat SARS-CoV-2 would be to neutralize the virus from entering cells by targeting the host ACE2 protein, since the chances of mutation in this will be very less (Walker and Burton, 2018; Karakus *et al.*, 2020). Proteases (3CLpro and PLpro) translated from viral RNA are essential for polyprotein processing of

SARS-CoV-2 and involved in replication and transcription of SARS-CoV-2 can serve as potent therapeutic targets (Prussia *et al.*, 2011; Sheahan *et al.*, 2020). The SARS-CoV-2 proteases act on polyproteins (PP1a and PP1ab) to release the nsps which are encoded by open reading frame (ORF1a/b) of virus (Sheahan *et al.*, 2020). Inhibiting virus entry into the cell and its replication combined with modulating the immune system could be a potential target for drug therapy (Sanders *et al.*, 2020). Currently, there are no available vaccines or specific medicines for the treatment of COVID-19.

All the countries and pharma giants in the world are working to come out with either vaccines or drugs which will be helpful in containing this global pandemic. In India, attempts were made to address this problem through Ayurveda and Siddha practices as well apart from development of drugs and vaccines, which were still widely used among the Indian population to combat diseases caused by viral infections such as jaundice, malaria, cholera *etc.*, (Gomathi *et al.*, 2020). Ayurveda is the age old practice of treating human ailments in India and provided remedies against many medical conditions. Medicinal herbs from India are promising in treating various illnesses (Gomathi *et al.*, 2020). Further, identification of phytochemicals from medicinal plants can be used as drugs for viral infection targeting viral receptors (Chang and Woo, 2003; Keyaerts *et al.*, 2007), viral integration (Kim *et al.*, 2010), reverse transcription, viral replication and viral protein translation (Mansouri *et al.*, 2009).

Extracts from *Andrographis paniculata* Wall (Kalmegh) and *Phyllanthus amarus* Schum. & Thonn were used in Ayurvedic medicinal systems and proven to have numerous medicinal properties (Niranjan *et al.*, 2010; Patel *et al.*, 2011). *A. paniculata* also known as ‘King of bitters’ belonging to *Acanthaceae* family (Pholphana *et al.*, 2013) is widely used to treat fever, diarrhoea, common cold. It consists of wide range of pharmacologically active substances such as andrographolides and its derivatives that have been showed anti-cancer, antimalarial, hepato-protective, antioxidant activities (Niranjan *et al.*, 2010) and reported to have potent antiviral activity against diverse group of viruses belonging to different families (Gupta *et al.*, 2017). It also been implicated in suppression of increased NOD-like receptor protein 3 (NLRP3), caspase-1, and interleukin-1 β molecules which are extensively involved in the pathogenesis of SARS-COV and likely SARS-CoV-2 as well (Liu *et al.*, 2020a, Liu *et al.*, 2020b). *Phyllanthus amarus* Schum. & Thonn. (Family: *Euphorbiaceae*) is one of a medicinal herb widely distributed in tropical and subtropical countries from Africa to Asia, South America and the West Indies. It is a rich source of secondary metabolites such as alkaloids, flavonoids, hydrolysable tannins, lignins, polyphenols, triterpenes, sterols and volatile oils (Patel *et al.*, 2011). It exhibits an array of

ethanopharmacological activities such as anti-inflammatory, hepatoprotective, nephroprotective, anti-amnesia, anti-cancer, diuretic, anti-oxidant, anti-viral, anti-bacterial, anti-hyperglycemic, anti-hypercholesterolemia and so on (Calixto *et al.*, 1998; Patel *et al.*, 2011).

Several Ayurvedic practitioners in India claiming Ayurveda medicine can cure Covid-19, which are not supported by enough scientific evidences. Nevertheless, the role of herbal extracts in addressing the human ailments cannot be ignored totally. Lack of proper experimental evidences might have made regulatory authorities to enforce not to sale the Ayurveda medicines as a curative agent of Covid-19. There are several Ayurveda tablets available in the Indian market claiming to boost immune system in the backdrop of Covid-19 outbreak. Here we discussed on the potential Ayurveda medicine prepared using *A. paniculata* and *P. amarus* against SARS-CoV-2 through the results of *in silico* analysis of interaction between SARS-CoV-2 proteins and secondary metabolites of these plants available in the databases. This provides some preliminary scientific evidence to harness the potential of Ayurveda medicines in combating SARS-CoV-2. However, this needs to be validated with experimental evidences required by the regulatory authorities such as large scale clinical trials.

Material and Methods

Sources of ligands and viral receptor proteins

The list of phytochemicals present in *P. amarus* and *A. paniculata* were obtained from previously published scientific literature (Chao and Lin, 2010; Gupta and Vaghela, 2019; Joseph and Raj, 2011; Nisar *et al.*, 2018; Pereira *et al.*, 2016; Tan *et al.*, 2016). A total of 35 compounds were selected for the molecular docking studies (21 from *P. amarus* and 14 from *A. paniculata*) (Table 1). Remdesivir, an antagonist of SARS-CoV-2 RdRp was chosen as a positive control (Yu *et al.*, 2020).

The three-dimensional (3D) conformers of the selected ligands were retrieved from PubChem (<https://pubchem.ncbi.nlm.nih.gov>) database in SDF and MOL formats. Similarly, the 3D structures of proteins determined using a biophysical technique such as X-ray crystallography or NMR spectroscopy are openly available in protein data bank were retrieved (www.rcsb.org). Four different viral targets were considered for docking studies viz., spike protein (S protein), 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro) and RNA dependent RNA polymerase (RdRp). The crystal structure of S protein and 3CLpro of SARS-CoV-2 available in the protein databank were retrieved for the current study. The PDB ID for S protein and 3CLpro are PDB ID: 6VSB, chains A, B, C) (Wrapp *et*

et al., 2020), and PDB ID: 6LU7, chain A) (Jin *et al.*, 2020), respectively. Crystal protein structures of PLpro and RdRp of SARS-CoV-2 were not available in the protein databank at the time of analysis. Hence, the crystal structure developed for the both proteins using the X-ray structure of PLpro of human coronavirus papain-like proteases (PDB ID: 4OVZ, chain A) (Baez-Santos *et al.*, 2014) and the solved RdRp structure (97.08% sequence identity with SARS-CoV-2) of SARS-HCoV (PDB ID: 6NUS, chain A) (Kirchdoerfer *et al.*, 2019) were downloaded for docking studies.

Preparation of ligands and target proteins

The retrieved 3D structures of the ligands were optimized using Avogadro version 1.2.0 (Hanwell *et al.*, 2012) with force field type MMFF94 and converted to PDB format using Open Babel version 3.1.1. (O'Boyle *et al.*, 2011). For further simplification of analysis, the optimized ligands with the lowest energy were loaded to AutoDock-MGL Tools (Morris *et al.*, 2009), the gasteiger charges were added and standard processes were used to obtain the PDBQT files. The downloaded 3D structures were checked for the presence of any improper bonds, side-chain anomalies and missing hydrogens using PyMOL software (DeLano, 2009). All the water molecules, complex molecules, ions and ligands of the proteins were removed in Biovia Discovery Studio 2020 (Biovia, 2020). The optimized PDB structures were uploaded to AutoDock-MGL Tool (Morris *et al.*, 2009), succinctly, polar hydrogens were added and standard processes were used to obtain the PDBQT files.

Active site prediction and molecular docking

The active sites of the proteins were determined using the Computed Atlas for Surface Topography of Proteins (CASTp) (<http://sts.bioe.uic.edu/castp/index.html?2011>) and Biovia Discovery Studio 2020. In the case of 3CLpro protein, the binding site was selected based on the location of co-crystallized inhibitor N3, which was developed using computer-aided drug design and has shown specific inhibition to SARS and MERS with good binding affinity in the binding pockets of crystal structure of 3CLpro (Jin *et al.*, 2020). The optimized ligands and proteins in PDBQT format were subjected to molecular docking with the aid of AutoDock Vina software (Trott and Olson, 2010). AutoDock Vina predicts the interaction between protein and ligand by utilizing its scoring function (binding affinity). In the process of molecular docking, based on predicted active sites, the grid box was set to 60 Å × 60 Å × 60 Å centered at 225.616, 226.490, 225.337 (XYZ coordinates) for spike protein, grid box 26 Å × 26 Å × 26 Å centered at -10.712, 12.411, 68.8312 (XYZ coordinates) for 3CLpro, grid box 60 Å × 60 Å × 60 Å centered at -8.611, 38.916, -41.012 (XYZ coordinates) for PLpro and grid box 60 Å × 60 Å × 60 Å centered at 138.751, 163.504, 136.636 (XYZ coordinates) for RdRp.

The output file obtained after docking analysis consists of top 9 binding poses with their respective binding affinity in kcal/mol. The ligand binding pose showing highest binding affinity with least root mean square deviation (RMSD) was selected. The protein-ligand interaction in 3D structures was visualized in PyMOL. Similarly, 2D structure was visualized in Biovia Discovery studio 2020. The 3D visualization represents the exact location or the binding pocket of the target protein. Whereas, the 2D structure visualization represents the different bonds formed between the amino acid residues of the viral target protein and the ligand. The workflow of *in silico* molecular docking analysis has been represented in figure 1.




Figure 1: The workflow of molecular docking analysis of phytochemicals present in *P. amarus* and *A. paniculata* with four proteins (S protein, 3CLpro, PLpro and RdRp) targets of SARS-CoV-2. The phytochemicals of the two plant species were obtained from PubChem (<https://pubchem.ncbi.nlm.nih.gov>) database in SDF and MOL formats. The 3D structures of proteins available in protein data bank were retrieved (www.rcsb.org). The detailed protocol is given in the material and methods.

ADME and other pharmacokinetic properties

The drug-likeness analysis was carried out based on Lipinski's rule of five (Lipinski, 2004). Absorption, Distribution, Metabolism, and Excretion (ADME) are pharmacokinetic properties of a ligand that deals primarily with its absorption, distribution, metabolism and excretion in the human body. The major parameter, Lipinski's rule of five was generated using SWISSADME (Daina *et al.*, 2017) for evaluating the pharmacological significance. The ligands in PDB format were converted to canonical SMILES format and uploaded to SWISSADME prediction (<http://www.swissadme.ch>). Properties such as solubility (logS), human intestinal absorption (HIA) and carcinogen were obtained from admetSAR (<http://lmmd.ecust.edu.cn/admetsar2>).

Results and Discussion

Impact of Covid-19 is having catastrophic effect on human health and life. The scientific communities from the nuke and corner of the world have scrupulously engaged in developing the drug or vaccine against SARS-CoV-2, causal agent of Covid-19. The current study discusses on the potential of phytochemicals present in two medicinal plants used in the Ayurveda, an age old medical practice in India. Plants/herbal extracts part of Ayurveda medicines are known to boost immunity in humans, which is crucial for fighting against microbial enemies (Kumar *et al.*, 2017). Plant extracts from *P. amarus* and *A. paniculata* have been extensively used in Ayurveda for curing various human ailments (Niranjan *et al.*, 2010; Patel *et al.*, 2011). The herbal extracts may have several phytochemicals, few of them might be playing role in neutralizing the pathogens. Binding interaction between a pathogen protein and ligand derived from herbal extracts may result in inhibition of the activity of pathogen protein. Hence, to understand and determine the potency of the plant extracts against cataclysmic virus SARS-CoV-2, about 21 compounds present in *P. amarus* and 14 compounds present in *A. paniculata* were used for molecular docking simulation with four SARS-CoV-2 receptor targets.

Prior to the docking analysis, the ligands were optimized by minimizing the energy with force field type MMFF94, this helps in removing clashes among atoms and develop a stable starting pose of the ligands for binding interaction (Klebe *et al.*, 2006). The docking coupled with a scoring function can be utilized to evaluate a large number of potential drugs *in-silico* (Monika *et al.*, 2010). In the process of molecular docking, generally, the binding affinity lesser than the upper threshold (-6 kcal/mol) is regarded as a *cut off* value for determining good binding affinity between ligand and protein (Shityakov *et al.*, 2014). Of the

35 compounds screened from two plant species (Table 1), three compounds (cinnamic acid, Phenylalanine and farnesyl farnesol) did not qualify as per the threshold binding affinity to neutralize SARS-CoV-2 proteins.

In the recent clinical trials, remdesivir, a nucleotide analogue of adenosine triphosphate has been reported to be a potential prodrug against SARS-CoV-2 infection (Gao *et al.*, 2020). It was originally developed for treating viral infection caused by Ebola and Marburg virus but was also found effective against SARS and MERS (Elfiky, 2020). Hence, remdesivir has been used as a positive control in the current study. During virus replication, the RdRp mistakenly incorporates remdesivir into its genome, which results in stalling of replication (Wang *et al.*, 2020). In our study, remdesivir has shown good interaction with RdRp protein (Table 1) with the binding affinity of -7.6 kcal/mol. Similarly, it has shown a good binding affinity with 3CLpro (-7.90 kcal/mol), S protein (-8.00 kcal/mol) and PLpro (-9.50 kcal/mol) (Table 1) and might be having some role in inhibiting SARS-CoV-2. Many recent computational investigations also showed inhibition activity of remdesivir with various viral receptors of SARS-CoV-2 (Murugan *et al.*, 2020; Elfiky, 2020; Hall and Feng, 2020). This shows that the prodrug might be effective against all the four viral receptors.

The 3D and 2D visualization of top three phytochemicals along with positive control remdesivir based on binding affinity with respective viral receptor protein has been represented in figure 2 and 3, respectively. Hydrogen bond energy is the major contributor in dock score. Hydrogen bond formation between ligand structures and viral receptors is responsible for inhibition of the target protein and it reflects the firmness of bonding between the protein and ligand (Chen *et al.*, 2016). Selected phytochemicals from *P. amarus* and *A. paniculata* used in the current docking studies against SARS-CoV-2 proteins shown very good dock score above the threshold cut off of -6 kcal/mol. Ligand structures and necessary hydrogen bond formation between phytochemical with respective viral receptor has been illustrated in table 2 and supplementary figure 1.




Figure 2: 3D visualization of interaction between SARS-CoV-2 proteins with representative phytochemicals. **A:** S protein (6VSB) with a) Geraniin, b) Furosin, c) Quercetin-3-O-glucoside, d) Remdesivir (positive control). **B:** 3CLpro (6LU7) with a) Geraniin, b) Furosin, c) Corilagin, d) Remdesivir (positive control). **C:** PLpro (4OVZ) with a) Quercetin-3-O-glucoside, b) Hinokinin, c) Astragaloside IV, d) Remdesivir (positive control). **D:** RdRp (6NUS) with a) Corilagin, b) Furosin, c) Geraniin, d) Remdesivir (positive control).




Figure 3: 2D visualization of interaction between SARS-CoV-2 proteins with representative phytochemicals. **A:** S protein (6VSB) with a) Geraniin, b) Furosin, c) Quercetin-3-O-glucoside, d) Remdesivir (positive control). **B:** 3CLpro (6LU7) with a) Geraniin, b) Furosin, c) Corilagin, d) Remdesivir (positive control). **C:** PLpro (4OVZ) with a) Quercetin-3-O-glucoside, b) Hinokinin, c) Astragalin, d) Remdesivir (positive control). **D:** RdRp (6NUS) with a) Corilagin, b) Furosin, c) Geraniin, d) Remdesivir (positive control).

Interaction between spike glycoprotein (S protein) (6VSB) and phytochemicals

S protein of the SARS-CoV-2 latch onto human angiotensin-converting enzyme 2 (ACE2) receptor and undergo structural changes that allow the viral membrane to fuse with the cell membrane of the host (Walls *et al.*, 2020). Despite the high similarity between sequences and structures of SARS and SARS CoV-2, the drugs successfully used to cure

SARS are ineffective in case of this novel virus (Fani *et al.*, 2020). This indicates that more number of potential molecules should be screened to find an effective molecule.

The molecular docking analysis of S protein of the SARS-CoV-2 with 21 selected phytochemicals from *P. amarus* showed that majority of the compounds bind to S protein with favourable binding energy ranging from -6.10 kcal/mol (for Phyllanthin) to -10.60 kcal/mol (for geraniin) (Table 1). When the binding energy of phytochemicals was investigated, nine compounds *viz.*, geraniin (-10.60 kcal/mol), furosin (-10.20 kcal/mol), astragalin (-9.80 kcal/mol), quercetin-3-O-glucoside (-9.80 kcal/mol), quercitrin (-9.20 kcal/mol), corilagin (-8.80 kcal/mol), hinokinin (-8.40 kcal/mol), kaempferol (-8.30 kcal/mol) and quercetin (-8.10 kcal/mol) exhibited highest binding affinity. Interestingly, the phytochemicals belonging to the flavonoids and tannins of *P. amarus* have shown a very high affinity with the target protein. Molecular dynamic simulation studies also reported that quercetin and kampferol bind with the ACE2-S complex with low binding free energy (Pandey *et al.*, 2020). The antiviral bioactivities of many flavonoids from medicinal plants were reported by several studies (Thayil *et al.*, 2016; Zakaryan *et al.*, 2017; Jo *et al.*, 2020). Among all compounds, geraniin exhibited (-10.60 kcal/mol) highest docking score with S protein. THR302, ILE312, GLN314, ARG765 amino acid residues were involved in forming four hydrogen bonds in the binding pocket of S protein (Table 2, Figure 3)

In binding interaction between phytochemical compounds (14) from *A. paniculata* with S protein of the SARS-CoV-2 the docking score ranged from -7.30 (for andrograpanin) and -9.10 kcal/mol (for isoandrographolide) (Table 1). Of the 14 compounds, five compounds; isoandrographolide (-9.10 kcal/mol), 19-O-acetyl-14-deoxy-11, 12-didehydroandrographolide (-8.40 kcal/mol), neoandrographolide (-8.20 kcal/mol) and 5-hydroxy-7, 8, 2', 5'-tetramethoxy flavone (-8.20 kcal/mol) shown better binding affinity as compared to remdesivir (-8.00 kcal/mol). Isoandrographolide has properly positioned into the binding pocket constructed by hydrogen bonding with GLU773 and ARG1019 amino acids of S protein exhibited highest (-9.10 kcal/mol) binding affinity (Table 2, Figure 2). Totally, 13 compounds from *P. amarus* and *A. paniculata* have shown better inhibitory activity against S protein.

Interaction between 3-chymotrypsin like protease (3CLpro) (6LU7) and phytochemicals

The SARS-CoV-2 protease enzyme, 3CLpro, involved in C-terminal cleavage of virus polyprotein is a potential target for drug discovery to SARS-CoV-2, since it controls replication (Qmar *et al.*, 2020). Hence, this potential target was evaluated with the selected 35 compounds from *P. amarus* and *A. paniculata*. Before docking simulation, the target site for

viral receptor protein was selected based on the location of co-crystallized inhibitor N3 as this target site has been considered to be the most commending site for ligand interaction (Murugan *et al.*, 2020).

The binding affinity of compounds to 3CLpro ranged from -6.10 kcal/mol (for andrograpanin) to -9.30 kcal/mol (for geraniin) (Table 1). Among 21 phytochemicals derived from *P. amarus*, six compounds viz., geraniin (-9.30 kcal/mol), furosin (-8.70 kcal/mol), corilagin (-8.70 kcal/mol), quercitrin (-8.60 kcal/mol), astralagin (-8.40 kcal/mol) and quercetin-3-O-glucoside (-8.20 kcal/mol) have shown better binding affinity as compared to remdesivir (-7.90 kcal/mol) (Table 1). The compounds belong to tannins (geraniin, furosin and corilagin) and flavonoids (quercitrin, astralagin, and quercetin-3-O-glucoside) are found to have good inhibitory action on 3CLpro. Several reports have been shown antiviral effect of flavonoids (Gescher *et al.*, 2010; Chen *et al.*, 2012). Recently, Adem *et al.*, (2020) evaluated 80 flavonoids compounds present in different medicinal plants against 3CLpro of SARS-CoV-2. Among them, hesperidin, rutin, diosmin, apiiin, diacetylcurcumin, (E)-1-(2-Hydroxy-4-methoxyphenyl)-3-[3-[(E)-3-(2-hydroxy-4-methoxyphenyl)-3-oxoprop-1-enyl] phenyl] prop-2-en-1-one, and beta, beta'-(4-Methoxy-1,3-phenylene) bis(2'-hydroxy-4',6'-dimethoxyacrylophenone) have shown effective binding affinity with SARS-CoV-2 3CLpro. The flavonoids from the two plant species used in the present study have higher binding affinity to protease than flavonoids reported by Adem *et al.* (2020). Geraniin, with the highest binding affinity of -9.30 kcal/mol has formed five hydrogen bonds with the amino acid residues, LEU141, GLY143, SER144, CYS145, THR190 of 3CLpro (Table 2, Figure 3).

The docking score for compounds present in *A. paniculata* ranged from -6.10 kcal/mol (for andrograpanin) to -7.80 kcal/mol (for neoandrographolide) (Table 1) which is on par with the remdesivir showing the score of -7.90 kcal/mol. During replication of the viral genome, the 3CLpro cleaves the C-terminal of polypeptide protein at 11 distinct sites to generate various nsps (Qmar *et al.*, 2020). Hence, the phytochemicals present in the extracts of *P. amarus* might hamper the activity of the protease enzyme there by inhibiting the process of virus multiplication.

Interaction between papain like protease (PLpro) (4OVZ) and phytochemicals

The SARS-CoV-2 another protease enzyme, PLpro known to be involved in cleaving of N-terminal of viral polyprotein which is also an important antiviral drug target. It also plays a crucial role in its replication along with 3CLpro (Baez-Santos, 2015). The 3D structure of PLpro used in the docking simulation is the x-ray structure of SARS-CoV, which has the highest similarity with the PLpro of SARS-CoV-2 (Zhou *et al.*, 2020).

The binding energy of phytochemicals present in *P. amarus* ranged from -6.30 kcal/mol (for cinnamic acid) to -10.30 kcal/mol (for quercetin-3-O-glucoside) (Table 1). Four compounds; quercetin-3-O-glucoside (-10.30 kcal/mol), hinokinin (-9.80 kcal/mol), astragalin (-9.70 kcal/mol) and kaempferol (-9.60 kcal/mol) from *P. amarus* have exhibited better binding energies compared to remdesivir (-9.50 kcal/mol). Apart from this, the binding affinities of furosin (-9.20 kcal/mol) and geraniin (-9.20 kcal/mol) are reasonably well with that of the positive control, remdesivir. Quercetin-3-O-glucoside has the maximum dock score of -10.30 kcal/mol and shown its binding to HIS74, ARG83, TYR155, ASN157, HIS176 amino acid residues of viral protein at the binding pocket of PLpro with eight hydrogen bonds (Table 2, Figure 3)

The binding affinity of compounds from *A. paniculata* with PLpro ranged from -6.80 kcal/mol (for andrograpanin) to -9.00 kcal/mol (for 5-Hydroxy-7,8-dimethoxyflavone). Even though binding affinities of all the 15 compounds falls between -6.00 kcal/mol and less than the dock score of positive control remdesivir (-9.5 kcal/mol), they also might have inhibitory effects on the activity of PLpro. The results suggest that, among the promising phytochemicals from *P. amarus* and *A. paniculata* docked with PLpro, flavonoids (quercetin-3-O-glucoside and astragalin) and phenyl propanoid (hinokinin) have exhibited better binding affinity. The SARS-CoV-2 PLpro is essential virus replication (Baez-Santos *et al.*, 2015) and any compound having good binding affinity with inhibitory effects will be of immense potential in containing this virus. The flavonoids and phenyl propanoids showing good affinity binding abilities might serve as lead molecules for the discovery of novel drugs to SARS-CoV-2.

Interaction between RNA dependent RNA polymerase (RdRp) (6NUS) and phytochemicals

The RdRp plays a major role in the replication and transcription of SARS-CoV-2 genome (Aftab *et al.*, 2020). The RdRp used in the current study is the solved structure of SARS-CoV having 97.08 percent sequence identity with the RdRp of SARS-CoV-2 (Kirchdoeffer and Ward, 2020).

Among 21 compounds from *P. amarus* screened against RdRp, epibubbialine has shown lowest dock score of -6.30 kcal/mol (below -6.0 kcal/mol is considering as having good binding affinity) and corilagin has shown highest dock score of -9.30 kcal/mol (Table 1). Seven compounds; corilagin (-9.30 kcal/mol), furosin (-9.10 kcal/mol), geraniin (-9.10 kcal/mol), quercetin (-8.60 kcal/mol), hinokinin (-8.20 kcal/mol), querecetrin (-8.10 kcal/mol) and querecetin-3-O-glucoside (-7.70 kcal/mol) from *P. amarus* exhibited better dock score

compared to the RdRp antagonist remdesivir (-7.60 kcal/mol). Corilagin with high binding affinity of -9.30 kcal/mol has interacted with active site residues, TYR129, HIS133, LEU207, ASN705, GLN724 of RdRp of virus through five hydrogen bonds (Table 2, Figure 3)

Five compounds, neoandrographolide (-8.50 kcal/mol), isoandrographolide (-8.30 kcal/mol), 14-deoxy-14,15-didehydroandrographolide (-7.90 kcal/mol), 14-Deoxyandrographolide (-7.80 kcal/mol) and 5-hydroxy-7, 8, 2',5'-tetramethoxy flavone (-7.80 kcal/mol) from *A. paniculata* have shown better binding energy affinity compared to remdesivir (-7.60 kcal/mol) (Table 1). Among these, neoandrographolide exhibited higher dock score of -8.50 kcal/mol and interacted with ALA125, ASP126, ARG132, HIS133 amino acid residues of RdRp through four hydrogen bonds (Table 2, Figure 3).

In general, the flavonoids (astragalin, kaempferol, quercetin, quercetin-3-O-glucoside and quercetrin), a phenyl propanoid (hinkonin) and tannins (corilagin, furosin and gerannin) from *P. amarus* and a bioactive compound (isoandrographolide), diterpenes (14-deoxy-14,15-didehydroandrographolide, 14-Deoxyandrographolide, 19-O-acetyl-14-deoxy-11,12-didehydroandrographolide, Neoandrographolide) and a flavonoid (5-hydroxy-7,8,2',5'-tetramethoxy flavone) from *A. paniculata* have shown good binding affinities with all the four SARS-CoV-2 target proteins. The natural compounds obtained from the medicinal plants have been used in case of two previous coronavirus outbreaks of MERS-CoV and SARS-CoV (Li *et al.*, 2005; Lin *et al.*, 2005). Similarly, strong interaction of tannins (polyphenols) from green tea, epigallocatechin gallate, epicatechingallate and gallic acid with viral receptor (3CLpro) of SARS-CoV-2 was shown (Ghosh *et al.*, 2020). The flavonoids and tannins interaction with proteins of SARS-CoV-2 *in vitro* may provide more insights into exploiting these compounds as potential SARS-CoV-2 inhibiting compounds and lead to novel drug development. Further, among all the phytochemicals, the geraniin has shown consistent interaction and very good binding affinity with all the viral protein receptors. The geraniin, extracted from *P. amarus* has shown to inhibit HIV-1 replication in HeLa CD4+ cells with 50% effective concentration (EC50) values ranging from 0.9 to 7.6 µg/ml (Notka *et al.*, 2004). This suggests that geraniin with multiple target binding ability in docking analysis with high dock score than remdesivir can be a potential candidate to harness as anti SARS-CoV-2 drug. However, this needs *in vitro* evaluation to authenticate the prediction studies.










Table 1: Dock score of interaction between phytochemicals from *Phyllanthus amarus* and *Andrographis paniculata* with SARS-CoV-2 proteins; S protein (PDB ID:6VSB), 3 chymotrypsin like protease (3CLpro) (PDB ID:6LU7), papain like protease (PLpro) (PDB ID:4OVZ) and RNA dependent RNA polymerase (RdRp) (PDB ID:6NUS).








Group	Sl. No	Compound	S protein	3CLpro	PLpro	RdRp
			Binding affinity (kcal/mol)	Binding affinity (kcal/mol)	Binding affinity (kcal/mol)	Binding affinity (kcal/mol)
Positive control	1	Remdesivir	-8.00	-7.90	-9.50	-7.60
Phytochemicals from <i>P. amarus</i>						
Alkaloids	1	Epibubbialine	-6.80	-5.90	-7.50	-6.30
	2	Isobubbialine	-7.40	-6.00	-7.70	-6.40
	3	nor-securinine	-6.80	-5.70	-7.30	-6.80
	4	Securinine	-7.10	-5.90	-7.70	-7.30
Flavanoids	5	Astragalin*	-9.80	-8.40	-9.70	-7.60
	6	Kaempferol*	-8.30	-7.70	-9.60	-7.00
	7	Quercetin*	-8.10	-7.50	-8.60	-8.60
	8	Quercetin-3-O-glucoside*	-9.80	-8.20	-10.30	-7.70
	9	Quercitrin*	-9.20	-8.60	-8.80	-8.10
Phenyl propanoid	10	Cinnamic acid	-5.80	-4.70	-6.30	-5.60
	11	Hinokinin*	-8.40	-7.40	-9.80	-8.20
	12	Niranthin	-6.30	-6.30	-7.60	-6.10
	13	Nirtetralin	-7.40	-6.60	-6.70	-7.00
	14	Phenylalanine	-5.50	-4.80	-6.00	-5.60
	15	Phyllanthin	-6.10	-5.70	-7.60	-6.40
Tannins	16	Corilagin*	-8.80	-8.70	-8.50	-9.30
	17	Furosin*	-10.20	-8.70	-9.20	-9.10
	18	Geraniin*	-10.60	-9.30	-9.20	-9.10
	19	Melatonin	-6.60	-5.80	-7.00	-5.50
Triterprnes	20	farnesyl farnesol	-5.20	-4.50	-5.80	-4.70
	21	Phenazine	-6.70	-5.80	-7.50	-7.00
Phytochemicals from <i>A. paniculata</i>						
Bioactive compounds	1	Andrograpanin	-7.30	-6.10	-6.80	-7.20
	2	Andrographolide	-7.90	-6.50	-8.00	-7.30
	3	Isoandrographolide*	-9.10	-7.00	-9.30	-8.30
Diterpenes	4	14-acetylandrographolide	-7.60	-6.70	-8.40	-7.00
	5	14-deoxy-11,12-didehydroandrographolide	-7.70	-7.60	-7.30	-7.10
	6	14-deoxy-14,15-didehydroandrographolide	-8.00	-6.80	-7.80	-7.90
	7	14-Deoxyandrographolide	-8.00	-7.30	-8.30	-7.80
	8	19-O-acetyl-14-deoxy-11,12-didehydroandrographolide	-8.40	-6.80	-8.80	7.10
	9	Deoxyandrographolide	-7.80	-7.30	-7.00	7.50
	10	Neoandrographolide	-8.20	-7.80	-7.80	-8.50
Flavanoids	11	5-hydroxy-7,8,2',3'-tetramethoxyflavone,	-7.60	-6.90	-8.40	-7.00
	12	5-hydroxy-7,8,2',5'-tetramethoxy flavone	-8.20	-7.60	-8.60	-7.80
	13	5-hydroxy-7,8-dimethoxyflavanone	-7.80	-7.20	-8.90	-7.30
	14	5-Hydroxy-7,8-dimethoxyflavone	-7.90	-7.50	-9.00	-7.50

Note: The docking score of respective phytochemicals higher than the positive control (remdesivir) has been denoted in bold.

“*” indicates the phytochemicals showing better binding affinity with all the viral proteins.

Table 2: Number of hydrogen bonds formed during the interaction between phytochemical structures with SARS-CoV-2 Proteins; S protein (PDB ID:6VSB), 3 chymotrypsin like protease (3CLpro) (PDB ID:6LU7), papain like protease (PLpro) (PDB ID:4OVZ) and RNA dependent RNA polymerase (RdRp) (PDB ID:6NUS). The interactions showing more binding affinity than remdesivir and SARS-CoV-2 are presented here.

Sl. No	Compound with PubChem ID	Structural and chemical formula	No. of H bonds	Proteins of SARS-CoV-2	Amino acid residues of viral receptor involved in hydrogen bonding with ligand
1	Remdesivir 121304016	 <chem>C27H35N6O8P</chem>	5	S protein	GLN954, ARG1014, ARG1019
			4	3CLpro	HIS41, AGR188, THR190
			4	PLpro	SER156, LEU163, TYR208, MET209
			1	RdRp	SER709
2	Astragalin 5282102	 <chem>C21H20O11</chem>	3	S protein	PHE970, ASP994, THR998
			2	3CLpro	SER144, ARG188
			4	PLpro	SER156, LYS158, ASP165, ARG167
3	Kaempferol 5280863	 <chem>C15H10O6</chem>	4	S protein	TYR756, ARG995, THR756
			5	PLpro	THR75, ASP77, ARG83, ASN157
4	Quercetin 5280343	 <chem>C15H10O7</chem>	4	S protein	THR549, ASP745, ASN978, ARG1000
			4	RdRp	GLU350, PRO323, ASN628, VAL675
5	quercetin-3-O-glucoside 5280804	 <chem>C21H20O12</chem>	5	S protein	PHE970, ARG995, THR998
			3	3CLpro	LEU141, HIS163, MET 165
			8	PLpro	HIS74, ARG83, TYR155,ASN157,HIS176
			3	RdRp	ALA125, HIS133
6	Quercitrin 5280459	 <chem>C21H20O11</chem>	8	S protein	ASP994, AGR995, PHE970, THR998
			1	3CLpro	ASN142
			1	RdRp	TYR732
7	Hinokinin 442879	 <chem>C20H18O6</chem>	4	S protein	THR573, LEU977,ASN978, AGR1000
			0	RdRp	
			1	PLpro	TYR269
8	Corilagin 73568	 <chem>C27H22O18</chem>	5	S protein	GLU773, LYS947, GLU1017, ASN1023
			6	3CLpro	GLY143, SER144, MET165, GLU166
			5	6NUS	TYR129, HIS133, LEU207, ASN705, GLN724
9	Furosin 10416810	 <chem>C27H22O19</chem>	4	S protein	ARG765, GLN954, AGG1014
			4	3CLpro	THR24, THR26, ASN142, GLY143
			6	PLpro	ASP165, PRO249, GLN270, TYR274
			7	RdRp	ARG132, THR710, ASP711, GLY712, ASN713, TYR732
10	Geraniin 3001497		4	S protein	THR302, ILE312, GLN314, ARG765
			5	3CLpro	LEU141, GLY143, SER144, CYS145, THR190
			2	PLpro	GLU251, TYR269

		 C ₄₁ H ₂₈ O ₂₇	8	RdRp	THR319, ASP390, LYS391, ARG349, PHE396, ARG457, ASN459
11	Isoandrographolide 343585	 C ₂₀ H ₃₀ O ₅	2	S protein	GLU773, ARG1019
			1	PLpro	TYR155
			0	RdRp	
12	14-deoxy-14,15-didehydroandrographolide 6473762	 C ₂₀ H ₂₈ O ₄	1	RdRp	SER236
13	14-Deoxyandrographolide 11624161	 C ₂₀ H ₃₀ O ₄	1	RdRp	SER236
14	19-O-Acetyl-14-deoxy-11,12-didehydroandrographolide 46179874	 C ₂₂ H ₃₀ O ₅	4	S protein	ARG319, LEU977, ARG1000
15	Neoandrographolide 9848024	 C ₂₆ H ₄₀ O ₈	2	S protein	GLU748, ASN856
			4	RdRp	ALA125, ASP126, ARG132, HIS133
16	5-hydroxy-7,8,2',5'-tetramethoxy flavone 16215023	 C ₂₅ H ₂₈ O ₁₂	4	S protein	GLN314, GLN613, ILE666, LYS733
			2	RdRp	GLN728, TYR728

ADME and other pharmacokinetic properties

The pharmacokinetic evaluation and ADME (absorption, distribution, metabolism and excretion) properties predictions of pharmacological compounds in advance are important methods to save huge monetary expenses in drug discovery (Zhu *et al.*, 2018). Apart from that, it mainly helps in reducing the potential risk during clinical development as it provides very crucial information to determine whether a compound is suitable to proceed to clinical stage. SWISS-ADME (<http://www.swissadme.ch>) and admetSAR (<http://lmmd.ecust.edu.cn/admetSAR2>) web servers were used to obtain the ADME and other pharmacokinetic properties of the selected compounds. Among the 35 compounds from *P. amarus* and *A. paniculata* evaluated against SARS-CoV-2 by *in silico* docking analysis, 15

compounds (9 compounds from *P. amarus* and 6 compounds from *A. paniculata* were selected for ADME and other pharmacokinetic properties predictions. All these 15 compounds selected showed better binding ability than the ramdesivir.

The ADME and pharmacokinetic properties of selected phytochemicals are given in the Table 3. Lipinski rule of five (Lipinski, 2004) is a thumb rule to evaluate the drug likeliness or to determine the pharmacological activities that would make it orally active drug in humans. According to the rule the compound should abide following criteria *i.e.*, i) molecular mass less than 500 Daltons, ii) high lipophilicity (expressed as logP less than 5), iii) less than five hydrogen bond donors and iv) less than 10 hydrogen bond acceptors (Petit *et al.*, 2012). Of 15 compounds along with ramdesivir screened, eight compounds (kaempferol, quercetin, hinokinin, isoandrographolide, 14-deoxy-14,15-didehydroandrographolide, 14-Deoxyandrographolide, 19-O-Acetyl-14-deoxy-11,12-didehydroandrographolide and neoandrographolide) did not violate any of the above rule. However, four compounds *viz.*, astralagin (HBA>10, HBD>5), quercetin-3-O-glucoside (HBA>10, HBD>5), quercitrin (HBA>10, HBD>5) and 5-hydroxy-7, 8, 2', 5'-tetramethoxy flavone (MW>500, HBA>10) along with positive control remdesivir have violated two rules. Three compounds belong to tannins *i.e.*, coriligan (MW>500, HBA>10, HBD>5), furosin (MW>500, HBA>10, HBD>5) and geraniin (MW>500, HBA>10, HBD>5) have violated 3 rules (Table 3). The violation of two or more criteria predicts a molecule to be a non-orally available drug (Lipinski, 2004). However, this rule applies only for oral drugs, the compounds violating the Lipinski's rule of five can be administered through other means after determining its side effects (Benet *et al.*, 2016).

The logS value is directly related to the solubility of the drug in water which ideally ranged between -6.5 and 0.5 (Nisha *et al.*, 2016). All the screened compounds lie within this range. The solubility of the molecules in water significantly facilitates drug developmental activities (Diana *et al.*, 2017). The selected phytochemicals have passed the carcinogenic test and all exhibit non-carcinogenic nature (Table 3). Among 15 phytochemicals, seven phytochemicals (kaempferol, quercetin, hinokinin, isoandrographolide, 14-deoxy-14,15-didehydroandrographolide, 14-Deoxyandrographolide and 19-O-acetyl-14-deoxy-11, 12-didehydroandrographolide) have shown high gastro-intestinal or human intestinal absorption. Remaining 8 phytochemicals (astragalin, quercetin-3-O-glucoside, quercetin, corilagin, furosin, geraniin, neoandrographolide and 5-hydroxy-7, 8, 2', 5'-tetramethoxy flavone) have exhibited low gastro-intestinal or human intestinal absorption. The positive control remdesivir also has low human intestinal absorption value. As all the compounds have

exhibited non-carcinogenic nature and good pharmacokinetic properties these compounds individually or in combination may be effective against the SARS-CoV-2. Further, inflammation of lungs resulting in breathing problem is a major symptom in the critical patients suffering from Covid-19 (Li and Ma, 2020). In addition to all the prediction studies, the plant extracts of *P. amarus* have shown anti-inflammatory properties in rat Kupffer cells (Kierner *et al.*, 2003). The pharmacokinetic predictions suggest that compounds from the two plants species studied in the current study are found to be biologically safe and can be utilized as therapeutics against SARS-CoV-19. However, more studies need to be conducted to decipher the exact mechanism involved in the interaction between these phytochemicals and the viral receptor proteins.

To summarize, all these current studies were done by *in silico* predictions of individual phytochemical originated from *P. amarus* and *A. paniculata*. The information generated here may provide some insights into exploring for potential drugs against SARS-CoV-2 from plants, which can result in discovery of novel drugs. Further, the Ayurveda medications using herbal extracts cannot be undermined in addressing human ailments. Because these extracts contain several compounds, which might have synergistic effect with action on multi-target sites of pathogen. However, the biggest problem in Ayurveda medicine is fixing the dose against the target pathogens. Optimization of this issue supported by scientific evidences for getting required clearances which will have far fetching impact in the harnessing Indian ancient knowledge of medication “Ayurveda” in treating the human ailments including Covid-19 caused by SARS-CoV-2, which threatened the mankind with global pandemic outbreak.

Table 3: Absorption, Distribution, Metabolism and Excretion (ADME) and other pharmacokinetic properties of selected phytochemicals from *Phyllanthus amarus* and *Andrographis paniculata*

S. L. No	Group	Compound	HIA	Carcinogens	logS value	MW	HBD	HBA	logP value	Rule of 5 violations
1	Positive control	Remdesivir	0.9135 (low)	NC	-3.474	602.58	4	12	3.4	2
2	Flavanoids	Astragalin	0.6347 (low)	NC	-2.449	448.38	7	11	1.29	2
3		Kaempferol	0.9881 (high)	NC	-3.142	286.24	4	6	1.7	0
4		Quercetin	0.9883 (high)	NC	-2.999	302.24	5	7	1.63	0
5		quercetin-3-O-glucoside	0.6468 (low)	NC	-2.449	464.38	8	12	0.94	2
6		Quercitrin	0.7322 (low)	NC	-3.497	448.38	7	11	1.6	2
7	Phenyl propanoid	Hinokinin	0.9784 (high)	NC	-3.113	354.35	0	6	3.08	0
8	Tannins	corilagin	0.8598 (low)	NC	-2.727	634.45	11	18	1.48	3
9		Furosin	0.8598 (low)	NC	-2.75	634.45	11	18	1.48	3
10		geraniin	0.8592 (low)	NC	-3.172	954.66	14	27	0.67	3
11	Bioactive compound	Isoandrographolide	0.9822 (high)	NC	-2.853	350.45	3	5	2.45	0
12	Diterpenes	14-deoxy-14,15-didehydroandrographolide	0.9773 (high)	NC	-2.927	332.43	2	4	2.96	0
13		14-Deoxyandrographolide	0.9899 (high)	NC	-2.816	334.45	2	4	2.79	0
14		19-O-Acetyl-14-deoxy-11,12-didehydroandrographolide	0.9764 (high)	NC	-4.139	374.47	1	5	3.48	0
15		Neoandrographolide	0.8124 (low)	NC	-3.313	480.59	4	8	3.37	0
16	Flavanoids	5-hydroxy-7,8,2',5'-tetramethoxy flavone	0.4104 (low)	NC	-2.678	520.48	4	12	3.22	2

HIA- Human intestinal absorption (probability), **logS**- Solubility, **MW**-Molecular weight (Dalton), **HBD**- Hydrogen bond donor, **HBA**- Hydrogen bond acceptor, **logP**-Lipophilicity, **Rule of 5 violations**- Lipinski rule of 5 and **NC**-Non carcinogen

Authors contribution: SH performed the bioinformatics work, SH, MN, HDV, MM, KSS and CNL involved in experimental design, CNL conceptualized work and provided the overall direction, all authors are involved literature mining and manuscript preparation. All authors read and approved the final manuscript

Competing interests: The authors declare that they have no competing interests.

References

- Adem, S., Eyupoglu, V., Sarfraz, I., Rasul, A and Ali, M. Identification of Potent COVID-19 Main protease (Mpro) inhibitors from natural polyphenols: An *in silico* strategy unveils a hope against Corona. *Preprints* 2020, doi: 10.20944/preprints202003.0333.v1.
- Aftab, S. O., Ghouri, M. Z., Masood, M. U., Haider, Z., Khan, Z., Ahmad, A. and Munawar, N., Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. *J. Transl. Med.*, 2020, **18**(1), 1-15.
- Báez-Santos, Y. M., et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. *J. Med. Chem.*, 2014, **57**(6), 2393-2412.
- Benet, L. Z., Hosey, C. M., Ursu, O. and Oprea, T. I., BDDCS, the rule of 5 and drugability. *Adv. Drug Delivery. Rev.*, 2016, *101*, 89-98.
- BIOVIA, D. S. Discovery studio visualizer, Release 2020, San Diego: Dassault Systemes, 2020.
- Boopathi, S., Poma, A. B. and Kolandaivel, P., Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. *J. Biomol. Struct. Dyn.*, 2020, doi: 10.1080/07391102.2020.1758788
- Calixto, J. B., Santos, A. R., Filho, V. C. and Yunes, R. A., A review of the plants of the genus *Phyllanthus*: their chemistry, pharmacology, and therapeutic potential. *Med. Res. Rev.*, 1998, *18*(4), 225-258.
- Chan, J. F. W., Kok, K. H., Zhu, Z., Chu, H., To, K. K. W., Yuan, S. and Yuen, K. Y., Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with a typical pneumonia after visiting Wuhan. *Emerg. Microbes. Infect.*, 2020, *9*(1), 221-236.
- Chang, Y.S. and Woo, E.R., Korean medicinal plants inhibiting to Human Immunodeficiency Virus type 1 (HIV-1) fusion. *Phytother. Res.*, 2003, **17**(4), 426-429.
- Chao, W. W., and Lin, B. F., Isolation and identification of bioactive compounds in *Andrographis paniculata* (Chuanxinlian). *Chin. Med.*, 2010, **5**(1), 17.
- Chen, C., Qiu, H., Gong, J., Liu, Q., Xiao, H., Chen, X.W., Sun, B.L. and Yang, R.G., Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. *Arch. Virol.*, 2012, **157**(7), 1301-1312.
- Chen, D., Oezguen, N., Urvil, P., Ferguson, C., Dann, S.M. and Savidge, T.C., Regulation of protein-ligand binding affinity by hydrogen bond pairing. *Sci. Adv.*, 2016, **2**(3), 1501240.
- Cheng, V. C., Lau, S. K., Woo, P. C. and Yuen, K. Y., Severe acute respiratory syndrome coronavirus as an agent of emerging and re-emerging infection. *Clin. Microbiol. Rev.*, 2007, **20**(4), 660-694.

- Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G. and Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antivir. Res.*, 2020, **176**, 104742.
- Daina, A., Michielin, O. and Zoete, V., SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.*, 2017, **7**, 42717.
- DeLano, W. L., 2009. The PyMOL Molecular Graphics System <http://www.pymol.org>.
- Diana, M., Raij, T., Melis, M., Nummenmaa, A., Leggio, L. and Bonci, A., Rehabilitating the addicted brain with transcranial magnetic stimulation. *Nat. Rev. Neurosci.*, 2017, **18**(11), 685.
- Elfiky, A. A., Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life. Sci.*, 2020, **248**, 117477.
- Fani, M., Teimoori, A. and Ghafari, S., Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. *Future. Virol.*, 2020 **15**(5), 317–323
- Fehr, A. R. and Perlman, S., Coronaviruses: an overview of their replication and pathogenesis. In *Coronaviruses*, Humana Press, New York, NY. 2015, 1-23
- Gaba, M., Gaba, P., Singh, S. and Gupta, G.D., An overview on molecular docking. *Int. J. Drug. Dev. Res.*, 2010, **2**(2), 219-231.
- Gao, Y., et al., Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science*, 2020, **368**: 779–782
- Gescher, K., Hensel, A., Hafezi, W., Derksen, A. and Kühn, J., Oligomeric proanthocyanidins from *Rumex acetosa* L. inhibit the attachment of herpes simplex virus type-1. *Antivir. Res.*, 2011, **89**(1), 9-18.
- Ghosh, R., Chakraborty, A., Biswas, A. and Chowdhuri, S., Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors—an *in silico* docking and molecular dynamics simulation study. *J. Biomol. Struct. Dyn.*, 2020, doi: 10.1080/07391102.2020.1779818.
- Glowacka, I., Bertram, S., Müller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirss, K. and Niemeyer, D., Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J. Virol.*, 2011, **85**(9), 4122-4134.
- Gomathi, M., Padmapriya, S. and Balachandar, V., Drug studies on Rett syndrome: from bench to bedside. *J. Autism. Dev. Disord.*, 2020, **50**, 2740–2764.
- Gorbalenya, A. E. et al., The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.*, 2020, **5**, 536-544.
- Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan, K. S., Wang, D. Y. and Yan, Y., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil. Med. Res.*, 2020, **7**(1), 1-10.
- Gupta, M., and Vaghela, J. S., Recent advances in pharmacological and phytochemistry studies on *Phyllanthus amarus*. *J. Pharm. Biosci.*, 2019, **7**(1), 1-8.
- Gupta, S., Mishra, K. and Ganju, L. Broad-spectrum antiviral properties of andrographolide. *Arch. Virol.*, 2017, **162**(3), 611–623

- Hall Jr, D.C. and Ji, H.F., A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. *Travel. Med. Infect. Di.*, 2020, **35**,101646.
- Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E. and Hutchison, G. R., Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. *J. Cheminf.*, 2012, **4**(1), 1-17.
- Jin, Z. et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. *Nature* 2020, 582, 289-293.
- Jo, S., Kim, S., Shin, D. H. and Kim, M. S., Inhibition of SARS-CoV 3CL protease by flavonoids. *J. Enzyme. Inhibition. Med. Chem.*, 2020, **35**(1), 145-151.
- Joseph, B., and Raj, S. J., An overview: pharmacognostic properties of *Phyllanthus amarus* Linn. *Int. J. Pharmacol.*, 2011, 7(1), 40-45.
- Karakus, U., Pohl, M. O. and Stertz, S., Breaking the convention: sialoglycan variants, coreceptors, and alternative receptors for influenza a virus entry. *J. Virol.*, 2020, **94**(4), 1-9.
- Keyaerts, E., Vijgen, L., Maes, P., Neyts, J. and Van Ranst, M., In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. *Biochem. Bioph. Res Co.*, 2004, **323**(1), 264-268.
- Kiemer, A. K., Hartung, T., Huber, C. and Vollmar, A.M., Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-κB pathway. *J. Hepatol.*, 2003, **38**(3), 289-297.
- Kim, Y., Narayanan, S. and Chang, K.O., Inhibition of influenza virus replication by plant-derived isoquercetin. *Antivir. Res.*, 2010, **88**(2), 227-235.
- Kirchdoerfer, R. N. and Ward, A.B., Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nat. Commun.*, 2019, **10**(1), 1-9.
- Klebe, G., Virtual ligand screening: strategies, perspectives and limitations. *Drug Discov. Today*, 2006, **11**(13), 580-594.
- Kumar, D., Kumari, K., Jayaraj, A., Kumar, V., Kumar, R.V., Dass, S.K., Chandra, R. and Singh, P., Understanding the binding affinity of nospapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures. *J. Biomol. Struct. Dyn.*, 2020, doi: 10.1080/07391102.2020.1752310
- Li, S. Y., Chen, C., Zhang, H. Q., Guo, H. Y., Wang, H., Wang, L., Zhang, X., Hua, S. N., Yu, J., Xiao, P. G. and Li, R. S., Identification of natural compounds with antiviral activities against SARS-associated coronavirus. *Antivir. Res.*, 2005, **67**(1), 18-23.
- Li, X. and Ma, X., Acute respiratory failure in COVID-19: is it “typical” ARDS? *J. Crit. Care.*, 2020, **24**(198), 1-5.
- Lin, C. W., Tsai, F. J., Tsai, C. H., Lai, C. C., Wan, L., Ho, T. Y., Hsieh, C. C. and Chao, P. D. L., Anti-SARS coronavirus 3C-like protease effects of *Isatis indigotica* root and plant-derived phenolic compounds. *Antivir. Res.*, 2005, **68**(1), 36-42.
- Lipinski, C. A. Lead-and drug-like compounds: the rule-of-five revolution. *Drug. Discov. Today. Technol.*, 2004, **1**(4), 337-341.
- Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A.C., Daniels, A.D., Jervy, S. and Albaiu, D., Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. *ACS. Cent. Sci.*, **2020(a)**, **6** (3), 315-331: doi: 10.1021/acscentsci.0c00272.

- Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J. and Liu, L., Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J. Med. Virol.*, 2020(b), **92**(6), 595-601.
- Machhi, J., Herskovitz, J., Senan, A.M. *et al.* The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. *J. Neuroimmune. Pharmacol.*, 2020, doi:org/10.1007/s11481-020-09944-5
- Mandal, B. The global emergence of severe acute respiratory syndrome coronavirus 2 in human. *Virusdisease.*, 2020, **31**, 67–70.
- Mansouri, S., Choudhary, G., Sarzala, P. M., Ratner, L. and Hudak, K.A., Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. *J. Biol. Chem.*, 2009, **284**(45), 31453-31462.
- Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M. and Taguchi, F., Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. *J. Virol.*, 2010, **84**(24), 12658-12664.
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.*, 2009, **30**(16), 2785-2791.
- Murugan, N. A., Pandian, C. J. and Jeyakanthan, J., Computational investigation on *Andrographis paniculata* phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials. *J. Biomol. Struct. Dyn.*, 2020, doi: 10.1080/07391102.2020.1777901.
- Niranjan, A., Tewari, S. K. and Lehri, A., Biological activities of kalmegh (*Andrographis paniculata* Nees) and its active principles: a review. *Indian. J. Nat. Prod. Resour.*, 2010, **1**(2), 125–135.
- Nisar, M. F., He, J., Ahmed, A., Yang, Y., Li, M. and Wan, C., Chemical components and biological activities of the genus *Phyllanthus*: A review of the recent literature. *Molecules*, 2018, **23**(10), 2567.
- Nisha, C. M., Kumar, A., Nair, P., Gupta, N., Silakari, C., Tripathi, T. and Kumar, A., Molecular docking and in silico ADMET study reveals acylguanidine 7a as a potential inhibitor of β -secretase. *Adv. Bioinformatics*, 2016,;doi.org/10.1155/2016/9258578
- Notka, F., Meier, G. and Wagner, R., Concerted inhibitory activities of *Phyllanthus amarus* on HIV replication in vitro and ex vivo. *Antivir Res.*, 2004., **64**(2), 93-102.
- O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T. and Hutchison, G.R., Open Babel: An open chemical toolbox. *J. Cheminf.*, 2011, **3**(1), 1-14.
- Pandey, P., Rane, J. S., Chatterjee, A., Kumar, A., Khan, R., Prakash, A. and Ray, S., Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. *J. Biomol. Struct. Dyn.*, 2020, doi: 10.1080/07391102.2020.1796811.
- Patel, J. R., Tripathi, P., Sharma, V., Chauhan, N. S. and Dixit, V. K., *Phyllanthus amarus*: ethnomedicinal uses, phytochemistry and pharmacology: a review. *J. Ethnopharmacol.*, 2011, **138**(2), 286-313.
- Pereira, R. G., Garcia, V. L., Rodrigues, M. V. N. and Martínez, J., Extraction of lignans from *Phyllanthus amarus* Schum. & Thonn using pressurized liquids and low pressure methods. *Sep. Purif. Technol.*, 2016, **158**, 204-211.

- Petit, J., Meurice, N., Kaiser, C. and Maggiora, G., Softening the rule of five—where to draw the line?. *Bioorg. Med. Chem.*, 2012, **20**(18), 5343-5351.
- Pholphana, N., Rangkadilok, N., Saehun, J., Rituechai, S. and Satayavivad, J., Changes in the contents of four active diterpenoids at different growth stages in *Andrographis paniculata* (Burm. f.) Nees (Chuanxinlian). *Chin. Med.*, 2013, **8**(1), 1-12.
- Prussia, A., Thepchatri, P., Snyder, J.P. and Plemper, R.K., Systematic approaches towards the development of host-directed antiviral therapeutics. *Int. J. Mol. Sci.*, 2011, **12**(6), 4027-4052.
- Qamar, M. T., Alqahtani, S. M., Alamri, M. A. and Chen, L. L., Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. *J. Pharm. Anal.*, 2020, doi:org/10.1016/j.jpha.2020.03.009.
- Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. and Cutrell, J. B., Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA*, 2020, **323**(18), 1824-1836.
- Sanders, J.M., Monogue, M.L., Jodlowski, T.Z. and Cutrell, J.B., Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA*, 2020, **323**(18).1824-1836.
- Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O. and Spahn, J. E., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat. Commun.*, 2020, **11**(1), 1-14.
- Shityakov, S., Sohajda, T., Puskas, I., Roewer, N., Forster, C. and Broscheit, J. A., Ionization states, cellular toxicity and molecular modeling studies of midazolam complexed with trimethyl- β -cyclodextrin. *Molecules*, 2014, **19**(10), 16861-16876.
- Simmons, G., Gosalia, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L. and Bates, P., Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc. Natl. Acad. Sci.*, 2005, **102**(33), 11876-11881.
- Tan, M. C. S., Oyong, G. G., Shen, C. C. and Ragasa, C.Y. Chemical constituents of *Andrographis paniculata* (Burm. F.) Nees. *Int. J. Pharmacogn. Phytochem. Res.*, 2016, **8**(8), 1398-402.
- Thayil, S. M. and Thyagarajan, S. P., Pa-9: A flavonoid extracted from *Plectranthus amboinicus* inhibits HIV-1 protease. *Int. J. Pharmacogn. Phytochem. Res.*, 2016, **8**(6), 1020-1024.
- Tortorici, M. Alejandra, and David Veessler. Structural insights into coronavirus entry. In *Adv. Virus. Res.*, 2019, **105**, 93-116.
- Trott, O. and Olson, A.J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput Chem.*, 2010, **31**(2), 455-461.
- Walker, L. M. and Burton, D. R., Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. *Nat. Rev. Immunol.*, 2018, **18**(5), 297-308.
- Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T. and Veessler, D., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*, 2020, **180**, 281–292.
- Wang, L., Wang, Y., Ye., D. and Liu. Q., Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. *Int. J. Antimicrob. Agents.*, 2020, **55**, 105948

- Wrapp, D. *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, 2020, **367**(6483), 1260-1263.
- Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China. *Nature*. 2020, **579**. (7798), 265-269. doi.org/10.1038/s41586-020-2008-3
- Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y. and Zhou, Q., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*, 2020, **367**(6485), 1444-1448.
- Yu, R., Chen, L., Lan, R., Shen, R. and Li, P. Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. *Int. J. Antimicrob. Agents*, 2020, 106012.
- Zakaryan, H., Arabyan, E., Oo, A. and Zandi, K., Flavonoids: promising natural compounds against viral infections. *Arch. Virol.*, 2017, **162**(9), 2539-2551.
- Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. and Fouchier, R. A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New Engl. J. Med.*, 2012, **367**(19), 1814–1820.
- Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y. and Zuo, W., Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. *BioRxiv.*, 2020, doi: 10.1101/2020.01.26.919985
- Zhu, J., Wang, J., Yu, H., Li, Y. and Hou, T., Recent developments of in silico predictions of oral bioavailability. *Comb. Chem. High. Throughput Screen.*, 2011, 14(5), 362–374
- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R. and Niu, P., A novel coronavirus from patients with pneumonia in China, 2019. *New Engl. J. Med.*, 2020, **382**(8), 727-733

Covid manuscript1.pdf (1.29 MiB)

[view on ChemRxiv](#) • [download file](#)
